Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09) : a randomised, multicentre, open-label, phase 3 trial

DSpace Repository

Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09) : a randomised, multicentre, open-label, phase 3 trial

Author: Weller, Johannes; Tzaridis, Theophilos; Mack, Frederic; Steinbach, Joachim Peter; Schlegel, Uwe; Hau, Peter; Krex, Dietmar; Grauer, Oliver; Goldbrunner, Roland; Baehr, Oliver; Uhl, Martin; Seidel, Clemens; Tabatabai, Ghazaleh; Brehmer, Stefanie; Bullinger, Lars; Galldiks, Norbert; Schaub, Christina; Kebir, Sied; Stummer, Walter; Simon, Matthias; Fimmers, Rolf; Coch, Christoph; Glas, Martin; Herrlinger, Ulrich; Schaefer, Niklas
Tübinger Autor(en):
Tabatabai, Ghazaleh
Published in: Lancet Oncology (2019), Bd. 20, H. 10, S. 1444-1453
Verlagsangabe: Elsevier Science Inc
Language: English
Full text: http://dx.doi.org/10.1016/S1470-2045(19)30502-9
ISSN: 1474-5488
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)